In Am J Trop Med Hyg 89: 570–577 by Fernandes Cota and others, there is an error in the tables. The authors found a mistake categorization of gender in the study database, which resulted in presentation of an inverted proportion between male and female patients, thereby generating an error in Tables 1 and 2 of the published study. The correct Tables appear here. The authors and the journal regret this error.

Table 1

Demographic and clinical characteristics of 113 HIV-infected patients who underwent diagnostic testing for VL

VariablePatients
Sex (male:female)76:37
Age, mean years + SD40, 42 ± 10.22
Previous VL (%)24/113 (21.2%)
CD4 count, median (25–75% interquartile range)*67 (37–164) cell/mm3
PCR-HIV-1 load, median (25–75% interquartile range)34.176 (79–184.370) copies/mm3
ARV therapy use (%)70/113 (61.9%)
Fever more than 14 days (%)81/113 (71.7%)
Cytopenia (%)111/113 (98.2%)
Splenomegaly (%)50/113 (44.2%)
Opportunist infection previously (%)67/113 (59.3%)

SD = standard deviation; VL = visceral leishmaniasis; PCR-HIV-1 = HIV load by real time polymerase chain reaction; ARV = anti-retroviral.

Available in 95 patients.

Available in 69 patients.

Table 2

Clinical and laboratorial characteristics of patients with target condition (visceral leishmaniasis) present or absent according to adjudication committee definition

 Target condition present, n = 46Target condition absent, n = 67P value
Age (mean ± SD)41.02 ± 10.840.0 ± 9.80.60
Sex (male:female)37:939:280.01
Anti-HVC presence2 (4.3%)6 (9.5%)0.44
HbsAg presence02 (3.2%)0.31
Illicit drug use16 (34.8%)27 (40.3%)0.58
Alcohol abuse31 (67.4%)40 (59.7%)0.39
Previous VL diagnosis20 (43.4%)4 (5.9%)0.00
Previous opportunist infection31 (67.4%)36 (53.7%)0.17
Previous schistosomiasis diagnosis3 (6.5%)7 (10.4%)0.05
Comorbidities13 (28.3%)16 (23.8%)0.64
CD4+ T cell count (25–75% IR)67 (6–864)*92 (5–483)0.18
HIV-PCR load copies/mm3 (25–75% IR)5.000 (0–65.712)78.132 (7.412–316.650)§0.01
Fever28 (60.8%)53 (79.1%)0.06
Cytopenia46 (100%)65 (97.0%)0.51
Splenomegaly on physical exam35 (76%)15 (22.4%)0.00
Death in 30 days4 (8.7%)8 (11.9%)0.02
ARV therapy use32 (69.6%)34 (50.7)0.15
ARV therapy regular use15/32 (46.8%)7/34 (20.6)0.01
Hemoglobin g/dl8.2 ± 1.69.1 ± 2.40.04
Leucocytes count cell/L (25–75% IR)2.0 (1.75–2.80) × 1093.3 (1.75–4.20) × 1090.005
Platelets count cell/L (25–75% IR)114 (82.75–173.75) ×109139 (90.50–244.50) ×1090.233
rK39 dipstick test positivity21/46 (45.6%)2/67 (3.0%)0.00
IFAT positivity28/46 (60.9%)7/67 (10.4%)0.00
DAT-LPC positivity41/46 (89%)8/59 (13.6%)0.00
Leishmania qPCR in peripheral blood positivity36/42 (85.7%)4/60 (6.7%)0.00
Median copies Leishmania qPCR in blood (25–75% IR)16.543 (108–70.209)66.436 (5066–36.479.000)0.56

SD = standard deviation; Anti-HVC = antibody to the hepatitis C virus; HbsAg = hepatitis B surface antigen; ARV = anti-retroviral; PCR-HIV = real time polymerase chain reaction for HIV-1; qPCR = real time polymerase chain reaction for Leishmania infantum.

Performed in 43 patients.

Performed in 52 patients.

Performed in 29 patients.

Performed in 40 patients.

Available in 35 patients.

Available in 4 patients.

Save